Anthracyclines are a class of chemotherapy drugs widely used in cancer treatment. Despite their efficacy, anthracyclines are associated with a significant risk of cardiotoxicity, which can lead to heart failure. Identifying genetic signatures associated with Anthracycline-Induced Cardiotoxicity (AIC) is crucial for predicting which patients are at higher risk and for developing preventive strategies. Mid-level molecular phenotypes, which encompass changes in gene expression, protein levels, and metabolite concentrations, offer a promising approach for identifying these genetic signatures. This review discusses the integration of mid-level molecular phenotypes with genetic data to uncover biomarkers of AIC hazard. We explore the current methodologies, highlight key findings, and propose future directions for research in this field.
HTML PDFShare this article
Human Genetics & Embryology received 309 citations as per Google Scholar report
